If You Invested in Conavi Medical Corp (CNVIF)

Conavi Medical Corp. (CNVIF) is a commercial-stage medical device company in the healthcare sector that focuses on imaging technologies to guide minimally invasive cardiovascular procedures. The company is described in its public communications as designing, manufacturing, and marketing systems used during common coronary interventions, with a particular emphasis on intravascular and intracoronary imaging.

According to multiple company news releases, Conavi’s core technology is its patented Novasight Hybrid™ System. This system is described as the first platform to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid™ System has regulatory clearance or approval for clinical use from the U.S. Food and Drug Administration (FDA), Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labour and Welfare, as stated in the company’s news disclosures.

Business focus and technology

Conavi states that it is focused on intravascular and intracoronary imaging solutions that can be used to guide percutaneous coronary interventions (PCI) and other minimally invasive cardiovascular procedures. Its hybrid platform is described as providing complementary information by combining IVUS and OCT in one integrated system. Company communications explain that this dual-modality approach is designed to give cardiologists a comprehensive view of coronary anatomy and to support more precise diagnosis and treatment planning in complex coronary artery disease.

In various news releases, Conavi highlights that its hybrid imaging platform is used to obtain simultaneous IVUS and OCT images through a single catheter and system. The company notes that this co-registered imaging can assist physicians with tasks such as identifying lesion characteristics, assessing plaque and stent details, and guiding stent placement during PCI. Case reports referenced by Conavi describe the use of Novasight Hybrid™ imaging in complex coronary cases, including scenarios where hybrid imaging helped distinguish plaque rupture from calcification and supported precise stent positioning.

Product evolution and next-generation system

Conavi’s disclosures distinguish between a first-generation Novasight Hybrid™ System and a next-generation Novasight Hybrid™ system. The first-generation system is repeatedly described as having regulatory clearance in the U.S., Canada, China, and Japan and as being used in clinical environments, including at cardiovascular care hospitals in North America.

The company also reports that it has developed a next-generation Novasight Hybrid™ IVUS/OCT intravascular imaging system and has submitted this system to the U.S. FDA for 510(k) clearance for coronary applications. In its public updates, Conavi states that this submission followed validation testing with leading interventional cardiologists and key opinion leaders. The company further notes that the next-generation system is intended to build on the regulatory foundation and clinical experience of the first-generation platform.

In describing the next-generation Novasight Hybrid™ system, Conavi highlights several design and performance goals, including:

• Enhanced IVUS and OCT image quality, as referenced in company news releases.
• A simplified user interface with added software features described as intended to improve ease of use.
• A system redesign aimed at improving catheterization laboratory workflow, including aspects such as system setup and bedside control, according to company communications.
• A design focus on reliability and suitability for routine clinical use in interventional cardiology settings, as described by the company.

Clinical and guideline context

Conavi’s public communications frequently reference the growing clinical importance of intravascular and intracoronary imaging in PCI. The company cites peer-reviewed publications and large-scale analyses that, according to those sources, associate IVUS and OCT guidance with improved outcomes in complex coronary interventions. Conavi also points to international clinical guidelines, including Class IA recommendations in guidelines from European and U.S. cardiology societies, which it describes as recommending the use of IVUS or OCT to guide PCI in certain complex cases.

In its news releases, Conavi presents its hybrid IVUS/OCT approach as aligned with this shift toward more frequent use of intracoronary imaging. The company notes that its platform is designed to address factors that have historically limited adoption of intravascular imaging, such as the need for separate IVUS and OCT systems, workflow complexity, and challenges in image interpretation. By offering a single system that can provide both modalities, Conavi states that it aims to simplify procedures and support both experienced and less experienced operators.

Market positioning and activities

Conavi describes itself as a commercial-stage company, indicating that it has moved beyond pure development into marketing and use of its imaging systems. The company reports activities such as:

• Participation in major interventional cardiology conferences, including Transcatheter Cardiovascular Therapeutics (TCT), where it features its hybrid IVUS/OCT imaging technology and participates in educational and training sessions.
• Engagement with interventional cardiologists and thought leaders through case presentations and intravascular imaging training sessions.
• Involvement in investor-focused events and webinars, where management discusses the company’s imaging technology and business strategy.

In its fiscal and operational updates, Conavi also refers to efforts related to manufacturing readiness, transfer to production of the next-generation Novasight Hybrid™ system, and building operational and commercial infrastructure to support potential U.S. commercialization, subject to regulatory clearance. The company’s communications mention technology transfer and licensing activities in China and limited product revenue from the first-generation system, indicating that its business model includes both product sales and licensing and milestone revenue associated with its imaging technology.

Regulatory and geographic footprint

Across multiple news releases, Conavi consistently states that the Novasight Hybrid™ System has 510(k) clearance from the U.S. FDA and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labour and Welfare. The company also notes that its first-generation system has been used in cardiovascular hospitals in North America and that it is based in Ontario, Canada, as reflected by its participation in Ontario-focused life sciences funding programs and events in Toronto.

Conavi’s shares trade under the symbol CNVIF on the OTCQB market and under CNVI on the TSX Venture Exchange, according to the company’s news releases. These listings position the company within the micro-cap segment of the public markets, and its communications reference participation by institutional investors in its financings.

Research, publications, and evidence base

The company regularly highlights peer-reviewed publications and case reports that feature its Novasight Hybrid™ system. Examples referenced in its news include:

• A case report in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) describing how hybrid IVUS/OCT imaging with Novasight Hybrid™ supported accurate diagnosis of plaque rupture and guided stent placement in a complex coronary artery case.
• A publication in The American Journal of Cardiology analyzing intracoronary imaging use during PCI in the United States, which the company cites as highlighting both underutilization and growing clinical importance of IVUS and OCT.

Conavi presents these publications as part of a broader body of clinical and academic evidence that, according to the cited sources, supports the role of intravascular imaging in improving PCI outcomes. The company’s communications emphasize that its hybrid platform is intended to contribute to this evolving field by providing a single system that can deliver both IVUS and OCT imaging.

Capital and funding initiatives

In its financial and corporate updates, Conavi reports that it has completed public equity financings and has entered into an agreement with the Province of Ontario under the Life Sciences Scale-Up Fund. The company states that this agreement provides eligibility for up to a specified amount of non-dilutive funding to support commercialization activities related to the next-generation Novasight Hybrid™ system. Conavi also notes that U.S. institutional investors have participated in its financings.

These disclosures indicate that Conavi’s growth strategy involves a combination of equity capital and non-dilutive funding aimed at supporting regulatory submissions, manufacturing preparation, and planned commercial activities for its hybrid intravascular imaging systems, as described in its own public communications.

Stock and investor profile

For investors researching CNVIF stock, Conavi Medical represents a medical device company focused on intravascular imaging for coronary interventions, with a patented hybrid IVUS/OCT platform and an emphasis on minimally invasive cardiovascular procedures. Its public disclosures center on the development, regulatory status, and commercialization plans for the Novasight Hybrid™ System, as well as on clinical evidence and guideline developments that relate to intracoronary imaging during PCI.